TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation
Sign Up to like & getrecommendations! Published in 2020 at "Asian Journal of Pharmaceutical Sciences"
DOI: 10.1016/j.ajps.2020.01.002
Abstract: Limited clinical application of antibody-drug conjugates (ADCs) targeting tumor associated antigens (TAAs) is usually caused by on-target off-tumor side effect. Tumor-specific mutant antigens (TSMAs) only expressed in tumor cells which are ideal targets for ADCs.… read more here.
Keywords: drug conjugates; antibody; tumor specific; kras g12v ... See more keywords
Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Chemical Society"
DOI: 10.1021/jacs.7b02988
Abstract: The Ras proteins are essential GTPases involved in the regulation of cell proliferation and survival. Mutated oncogenic forms of Ras alter effector binding and innate GTPase activity, leading to deregulation of downstream signal transduction. Mutated… read more here.
Keywords: total chemical; variants oncogenic; oncogenic kras; chemical synthesis ... See more keywords
Abstract PR08: TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-pr08
Abstract: Background: KRAS mutations drive tumorigenesis in adenocarcinomas of the lung (30-40%), colon (40-50%) and pancreas (>90%). Recent clinical evidence demonstrates potent and durable anti-tumor activity of adoptively transferred KRAS-specific T cells in select patients with… read more here.
Keywords: kras g12v; cell lines; clinical development; specificity ... See more keywords
An in silico—in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2019.02572
Abstract: Targeting CD8+ T cells to recurrent tumor-specific mutations can profoundly contribute to cancer treatment. Some of these mutations are potential tumor antigens although they can be displayed by non-spliced epitopes only in a few patients,… read more here.
Keywords: kras g12v; pipeline; spliced epitope; cancer ... See more keywords